Ironwood Pharmaceuticals Inc
apraglutide
short bowel syndrome (SBS) with intestinal failure (SBS-IF)
Resolved
7days ago
Phase 3 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 3 trial results for apraglutide in short bowel syndrome (SBS) with intestinal failure (SBS-IF) are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“On track to begin site initiations for Phase 3 confirmatory trial of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) in the second quarter of 2026”